Ceretec ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
6. Parkinson disease
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-004238-85-ES (EUCTR) | 27/01/2016 | 10/12/2015 | Brain SPECT in premotor stage of Parkinson disease | Ictal brain SPECT in the premotor stage of Parkinson disease | Parkinson disease MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: CERETEC (TM) Estabilizado Product Name: Ceretec INN or Proposed INN: Ceretec Other descriptive name: TECHNETIUM (99MTC) EXAMETAZIME | IDIBAPS | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | Spain |